prioritize event-driven hard outcomespatient-important events such as all-cause death, MACE (major adverse cardiovascular events), kidney failure, or fracture, with follow-up continuing until a prespecified event count is reachedand incorporate immune and epimeric markers to link biologic responses with clinical endpoints
Furthermore, the absence of strong data from clinical trials on novel therapeutic targets, such as inflammasome inhibitors or microbiome-modulating agents, limits the strength of conclusions regarding their efficacy and safety in humans
2021 Dec 1;157(12):1456-1465
Copper peptides, specifically GHK-Cu, work differently
One of the striking features of GST is that each subunit has two ligand-binding sites - G site and H site (Figure 3), which together constitute the catalytic active site [62, 77]